Immunophotonics Announces 1st Patient Dosed in IP-IIO-622 Phase 1b/2a Clinical Trial in Advanced Solid Tumor Indications

SAINT LOUIS, MISSOURI, USA, January 24, 2023 /EINPresswire.com/ — Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, has announced the initiation of recruitment and the dosing of its first patient in a clinical trial assessing safety and efficacy of its lead asset in multiple solid tumor indications. This multinational clinical trial, denominated alternatively as IP-IIO-622 or INJECTABL-1, is sponsored by Immunophotonics and will be enrolling patients for treatment of colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma. The trial has been approved in Switzerland, the United Kingdom, and France, where leading physicians in both medical oncology and interventional oncology are serving as principal investigators.

There is still a significant unmet need for late-stage solid-tumor cancer patients. The principal objective of this study is to evaluate the immunologically mediated anticancer effects of IP-001 following the use of radiofrequency ablation (RFA) in patients with advanced solid tumors. RFA is an approved and well-established thermal ablation technique that is readily available at most hospitals and clinics. While RFA is routinely used to reduce a patient’s tumor burden and eliminate targeted tumors, the effects of this routine intervention are local, with limited immunological benefits. This new strategy could provide such benefits to patients by transforming a tumor ablation into a systemic immunotherapy – igniting the body’s immune system to attack cancer at the site of ablation and beyond.

Dr. Baskin-Bey, Chief Medical Officer of Immunophotonics, who is an international oncology biopharmaceutical veteran with more than 20 years’ experience in academia and industry, stated:
“This is another significant milestone that supports our advancing clinical development program, which leverages prior preclinical and clinical research to expand the potential of IP-001 to other cancer indications that have a tremendous unmet medical need. I am looking forward to employing my clinical trial expertise in analyzing the upcoming data sets on the safety and efficacy of IP-001, a novel local approach to cancer treatment that stimulates a systemic anti-tumor immune response in patients with solid-tumor cancers.”

Dr. Markus Joerger, Principal Investigator for the study at the Cantonal Hospital St. Gallen Clinic for Medical Oncology and Hematology, commented:
“I am thrilled to be a part of this clinical trial. IP-001 combines the promise of modern immunotherapy with the trend towards intratumoral treatment, and to be able to bring this novel treatment to patients in desperate need for new innovative treatment options is exciting.”

More information about IP-IIO-622 clinical trial and enrollment can be found at clinicaltrials.gov.

About IP-001
IP-001 is a proprietary glycan polymer that acts both as an antigen depot and a potent immune stimulant capable of inducing immunological responses against cancer. It is designed to (1) prolong the availability of the target antigens (whether it is sourced through formulation or tumoricidal therapies), (2) facilitate the recruitment and activation of innate immune cells such as antigen-presenting cells (APCs), (3) increase the uptake of the tumor antigens into the APCs, and (4) lead to a potent downstream adaptive immune response against the antigenic targets. This ignited systemic, adaptive immune response then seeks out and eliminates its target throughout the body.

About Immunophotonics
Immunophotonics, Inc. is a privately owned clinical-stage biotech company pioneering the field of Interventional Immuno-Oncology™. IP-001, the first asset from the company’s intellectual property platform, has the potential to overcome the local defenses of the tumor microenvironment to enable a tumor-specific anticancer immune response in multiple solid tumor indications. The company is in early Phase 2 development and is based in St. Louis, Missouri, USA.

Cautionary Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements. Such statements involve inherent risks and uncertainties, and numerous factors could cause actual results to differ materially from those made or implied herein. All information provided in this press release is as of the date of this press release, and Immunophotonics, Inc. undertakes no duty to update such information, except as required under applicable law.

Contact:
IR@immunophotonics.com

Related Links:
https://www.immunophotonics.com

Public Relations
Immunophotonics, Inc.
email us here
Visit us on social media:
Twitter
LinkedIn
Instagram

Recommended Posts